Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

BACKGROUND: A heterologous recombinant adenovirus (rAd)-based vaccine, Gam-COVID-Vac (Sputnik V), showed a good safety profile and induced strong humoral and cellular immune responses in participants in phase 1/2 clinical trials. Here, we report preliminary results on the efficacy and safety of Gam-...

Descripción completa

Detalles Bibliográficos
Autores principales: Logunov, Denis Y, Dolzhikova, Inna V, Shcheblyakov, Dmitry V, Tukhvatulin, Amir I, Zubkova, Olga V, Dzharullaeva, Alina S, Kovyrshina, Anna V, Lubenets, Nadezhda L, Grousova, Daria M, Erokhova, Alina S, Botikov, Andrei G, Izhaeva, Fatima M, Popova, Olga, Ozharovskaya, Tatiana A, Esmagambetov, Ilias B, Favorskaya, Irina A, Zrelkin, Denis I, Voronina, Daria V, Shcherbinin, Dmitry N, Semikhin, Alexander S, Simakova, Yana V, Tokarskaya, Elizaveta A, Egorova, Daria A, Shmarov, Maksim M, Nikitenko, Natalia A, Gushchin, Vladimir A, Smolyarchuk, Elena A, Zyryanov, Sergey K, Borisevich, Sergei V, Naroditsky, Boris S, Gintsburg, Alexander L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7852454/
https://www.ncbi.nlm.nih.gov/pubmed/33545094
http://dx.doi.org/10.1016/S0140-6736(21)00234-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7852454/
https://www.ncbi.nlm.nih.gov/pubmed/33545094
http://dx.doi.org/10.1016/S0140-6736(21)00234-8

Ejemplares similares